Hemispherx Biopharma, Inc.
(NYSE Amex Equities : HEB)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Loading HEB News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-0.78%71.011.0%$662.14m
AMGNAmgen Inc.
0.57%154.670.8%$509.58m
CELGCelgene Corporation
-0.85%112.661.0%$466.03m
ARIAARIAD Pharmaceuticals, Inc.
0.21%23.7516.4%$442.07m
BIIBBiogen Inc.
0.11%280.661.0%$398.14m
REGNRegeneron Pharmaceuticals, Inc.
-0.23%362.562.5%$365.69m
ALXNAlexion Pharmaceuticals, Inc.
-1.77%131.972.5%$347.73m
ILMNIllumina, Inc.
-0.52%159.743.8%$229.47m
CLVSClovis Oncology, Inc.
2.07%58.2917.9%$160.24m
INCYIncyte Corporation
-0.26%117.222.2%$158.22m
VRTXVertex Pharmaceuticals Incorporated
0.57%81.372.1%$144.14m
TSROTESARO, Inc.
-1.94%147.0015.0%$106.77m
IONSIonis Pharmaceuticals, Inc.
0.58%46.978.9%$101.63m
SRPTSarepta Therapeutics, Inc.
-4.59%32.6616.8%$101.57m
BMRNBioMarin Pharmaceutical Inc.
-1.78%84.624.9%$95.71m

Company Profile

Hemispherx Biopharma, Inc. is a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and the experimental immunotherapeutic/antiviral Ampligen. Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. Ampligen includes application as a treatment for Chronic Fatigue Syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Philadelphia, PA.